{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:00Z","timestamp":1791896340498,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":827,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Each year, approximately 55,000 individuals worldwide die from an infection due to the rabies virus. Rabies is a life\u2010threatening disease caused by an RNA virus that is usually transmitted to humans through bites from rabid animals. More recently, reports of transmission by means of organ transplantation have been reported. Since human rabies is nearly 100% fatal if prophylactic measures are not followed, an increased awareness of who should receive prophylaxis and when prophylaxis should be administered is necessary. Preexposure prophylaxis entails the administration of the rabies vaccine to individuals at high risk for exposure to rabies viruses (e.g., laboratory workers who handle infected specimens, diagnosticians, veterinarians, animal control workers, rabies researchers, cave explorers). Preexposure prophylaxis involves a three\u2010dose series of the rabies vaccine that may confer some protection from the virus while simplifying postexposure prophylaxis regimens. Postexposure prophylaxis consists of a multimodal approach to decrease an individual's likelihood of developing clinical rabies after a possible exposure to the virus. Regimens depend on the vaccination status of the victim and involve a combination of wound cleansing, administration of the rabies vaccine, and administration of human rabies immune globulin. If used in a timely and accurate fashion, postexposure prophylaxis is nearly 100% effective. Once clinical manifestations of rabies have developed, however, treatment options for rabies are limited, and to date, only seven individuals have survived rabies virus infection. Treatment of clinical rabies consists of medical support in an intensive care unit, using a multifaceted approach that includes supportive care, heavy sedation, analgesics, anticonvulsants, and antivirals. The recently developed Milwaukee Protocol added induction of therapeutic coma to supportive care measures and antivirals; however, its use has shown inconsistent outcomes.<\/jats:p>","DOI":"10.1592\/phco.29.10.1182","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T14:44:02Z","timestamp":1254321842000},"page":"1182-1195","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Overview, Prevention, and Treatment of Rabies"],"prefix":"10.1002","volume":"29","author":[{"given":"Andrea Julia","family":"Nigg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058092"},{"key":"e_1_2_1_3_2","unstructured":"Centers for Disease Control and Prevention.Rabies\u20142008. Available fromhttp:www.cdc.govrabies. AccessedDecember 16 2008."},{"key":"e_1_2_1_4_2","first-page":"1","volume-title":"Pharmacotherapy self\u2010assessment program","author":"Amsden JR","year":"2004"},{"issue":"50","key":"e_1_2_1_5_2","first-page":"1171","article-title":"Recovery of a patient from clinical rabies\u2014Wisconsin, 2004","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_6_2","unstructured":"BergquistL.Milwaukee journal sentinal. Brazilian boy with rabies in recovery.November 16 2008. Available fromhttp:www.jsonline.comfeatureshealth34532044.html. Accessed December 22 2008."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042140"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00041-8"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02877781"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/342387"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043018"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2008.03.010"},{"issue":"1","key":"e_1_2_1_13_2","first-page":"S30","article-title":"Rabies as a traveler's risk, especially in high\u2010endemicity areas","volume":"12","author":"Meslin FX","year":"2005","journal-title":"J Travel Med"},{"issue":"3","key":"e_1_2_1_14_2","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the advisory committee on immunization practices","volume":"57","author":"Manning SE","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_15_2","volume-title":"Imovax rabies (rabies vaccine) package insert","author":"Pasteur Sanofi","year":"2005"},{"key":"e_1_2_1_16_2","unstructured":"Centers for Disease Control and Prevention.Rabies vaccine supply situation 2009. Available fromhttp:www.cdc.govrabiesnewsRabVaxupdate.html. AccessedApril 13 2009."},{"key":"e_1_2_1_17_2","volume-title":"RabAvert (rabies vaccine) package insert","author":"Novartis","year":"2004"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801143180219"},{"key":"e_1_2_1_19_2","volume-title":"Red book, 2008 ed","author":"Anonymous","year":"2008"},{"key":"e_1_2_1_20_2","volume-title":"CDC travelers' health yellow book: rickettsial infections, 2008","author":"Eremeeva ME","year":"2008"},{"key":"e_1_2_1_21_2","volume-title":"HyperRAB S\/D (human rabies immune globulin) package insert","author":"Talecris Biotherapeutics","year":"2008"},{"key":"e_1_2_1_22_2","volume-title":"Imogam Rabies HT (human rabies immune globulin) package insert","author":"Sanofi Pasteur","year":"1999"},{"key":"e_1_2_1_23_2","volume-title":"Bats and rabies: a public health guide, 2008","author":"Centers for Disease Control and Prevention","year":"2008"},{"issue":"28","key":"e_1_2_1_24_2","first-page":"393","article-title":"Recommendation of the immunization practices advisory committee (ACIP) rabies prevention\u2014United States, 1984","volume":"33","author":"Centers for Disease Control and Prevention","year":"1984","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_25_2","unstructured":"World Health Organization. Technical report series.WHO expert consultation on rabies 2005. Available fromhttp:www.who.intrabies931enindex.html. AccessedNovember 19 2008."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071326"},{"key":"e_1_2_1_27_2","unstructured":"Centers for Disease Control and Prevention.ACIP provisional recommendations for the prevention of human rabies July 10 2009. Available fromhttp:www.cdc.govvaccinesrecsprovisionaldownloadsrabies\u2010july2009\u2010508.pdf. AccessedJuly 15 2009."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2006.7.275"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/344905"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050382"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280600902295"},{"key":"e_1_2_1_32_2","unstructured":"Medical College of Wisconsin.The Milwaukee protocol 2007. Available fromhttp:www.chw.orgdisplayPPFDocID33223router.asp. AccessedDecember 22 2008."},{"issue":"15","key":"e_1_2_1_33_2","first-page":"361","article-title":"Human rabies\u2014Indiana and California, 2006","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.8.1750"},{"key":"e_1_2_1_35_2","first-page":"395","volume-title":"Basic and clinical pharmacology","author":"Trevor AJ","year":"2007"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.65.2.350"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867003375335"},{"key":"e_1_2_1_38_2","first-page":"341","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Evers AS","year":"2006"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-11-199806010-00012"},{"issue":"1","key":"e_1_2_1_40_2","first-page":"33","article-title":"Treatment of rabies in mice and foxes with antiviral compounds","volume":"32","author":"Bussereau F","year":"1988","journal-title":"Acta Virol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6703.830"},{"issue":"1","key":"e_1_2_1_42_2","first-page":"69","article-title":"Effect of amantadine on rhabdovirus infection","volume":"11","author":"Superti F","year":"1985","journal-title":"Drugs Exp Clin Res"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.10.1182","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.10.1182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:44:46Z","timestamp":1761054286000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.10.1182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1592\/phco.29.10.1182"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.10.1182","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}